网站首页
代理品牌
产品中心
返回
- 品牌
  返回
- 分子生物学
  返回
- 细胞生物学
  返回
  - 培养基
  - 抗生素
  - 血清
  - 胰酶
  - 其他试剂
    返回
- 免疫学
  返回
- 耗材
  返回
- 仪器
  返回
- 类器官产品
  返回
产品信息
返回
服务支持
返回
关于诺宁
联系我们

OrganRegen-CHIR-99021（C252917）

产品中心 > 类器官产品 > OrganRegen-CHIR-99021（C252917）

OrganRegen-CHIR-99021（C252917）

CHIR-99021
货号：C252917
规格：10mg
品牌：OrganRegen

价格：￥2112.00

分享到：

规格：

10mg

产品详细

CHIR-99021

货号：C252917

规格：10mg

品牌：OrganRegen

产品介绍

DESCRIPTION

Background	CHIR-99021 is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy^[1][2][3].
Alias	Laduviglusib; CT99021
M. W t	465.34
Formula	C₂₂H₁₈C_l2N₈
CAS No	252917-06-9
Storage	Powder	-20°C	3 years
		4°C	2 years C₂₂H₁₈C_l2N₈
	In solvent	-80°C	6 months
		-20°C	1 month
Solubility	DMSO	16.67 mg/mL(35.82 mM)
	H₂O	< 0.1 mg/mL(insoluble)

BIOLOGICAL ALTIVITY

In Vitro

CHIR-99021 inhibits human GSK-3β with K_i values of 9.8 nM^[1]. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC₅₀=~5 nM) and GSK3α (IC₅₀=~10 nM), with little effect on other kinases^[4]. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC₅₀ of 4.9 mm^[2].

In Vivo

In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration^[1]. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX⁺ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5⁺ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h^[5].

REFERENCES

[1]. Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.

[2]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.

[3]. Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7(4):e35892.

[4]. Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004.

[5]. Wang X, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566.